Doxorubicin

BNF:
8.1.2
Status:
Red
Decision Date:
May 2016
 

Comments

RED:

NICE TA389: pegylated liposomal doxorubicin hydrochloride is recommended as an option for treating recurrent ovarian cancer.  (Decision date - May 2016).

NHS England drug - to be used in line with NHS England commissioning intentions.

 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app